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Abstract: Several natural products (NPs) have displayed varying in vitro activities against methicillin-
resistant Staphylococcus aureus (MRSA). However, few of these compounds have not been developed
into potential antimicrobial drug candidates. This may be due to the high cost and tedious and
time-consuming process of conducting the necessary preclinical tests on these compounds. In this
study, cheminformatic profiling was performed on 111 anti-MRSA NPs (AMNPs), using a few orally
administered conventional drugs for MRSA (CDs) as reference, to identify compounds with prospects
to become drug candidates. This was followed by prioritizing these hits and identifying the liabilities
among the AMNPs for possible optimization. Cheminformatic profiling revealed that most of the
AMNPs were within the required drug-like region of the investigated properties. For example, more
than 76% of the AMNPs showed compliance with the Lipinski, Veber, and Egan predictive rules for
oral absorption and permeability. About 34% of the AMNPs showed the prospect to penetrate the
blood–brain barrier (BBB), an advantage over the CDs, which are generally non-permeant of BBB.
The analysis of toxicity revealed that 59% of the AMNPs might have negligible or no toxicity risks.
Structure–activity relationship (SAR) analysis revealed chemical groups that may be determinants of
the reported bioactivity of the compounds. A hit prioritization strategy using a novel “desirability
scoring function” was able to identify AMNPs with the desired drug-likeness. Hit optimization
strategies implemented on AMNPs with poor desirability scores led to the design of two compounds
with improved desirability scores.
Keywords: cheminformatics; profiling; natural products; methicillin-resistant Staphylococcus aureus
(MRSA), hit prioritization; hit-to-lead optimization; drug-likeness; desirability score
1. Introduction
The incidence of bacterial resistance to antibiotics is growing at an alarming rate across the
globe. It is one of the major causes of morbidity, mortality, and economic burden [1–3]. In the
United States, about 2 million patients are infected with these bacteria, and more than
23,000 cases of death are annually attributed to infections that they cause [1,2]. Continuous
and inappropriate uses of antibiotics, including the transfer of resistance within and be-
tween unrelated species, are some of the major factors responsible for developing antibiotic
resistance [4,5]. A more serious concern the failure of pharmaceutical industries to develop
new antibiotics because of poor economic returns and regulatory obstacles [2]. All these
have contributed to the growing rate of resistance among pathogenic organisms.
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the commonly known
antibiotic-resistant bacteria and life-threatening pathogens. MRSA has developed resistance
to methicillin and other β-lactam drugs such as amoxicillin, cephalosporins, oxacillin,
penicillin, and tetracycline, which were formally used in its treatment [6]. This superbug
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has now left fewer treatment options available, thereby making it more challenging to
control. Recent studies have identified MRSA as a drug-resistant pathogen of international
concern, requiring urgent research to discover and develop new and potent antimicrobial
agents [7].
The various therapeutic advantages of compounds sourced from nature have been
reviewed [8–11]. In addition, about 80% of antibiotics that are recently approved for
treating many life-threatening infections are sourced from natural products (NPs) [10].
This success has been linked to the considerable bioactive or chemical spaces and broad
diversities of NPs, giving them an edge of uncovering distinct structural groups over those
obtained from synthetic antibiotics [12]. Therefore, it is anticipated that NPs might win the
fight against MRSA.
Researchers have reported the in vitro activities of NPs against multiple-drug-resistant
bacteria, including MRSA [13–15]. However, many of these compounds have not made
their way into drug development pipelines [16]. This lack of progress can be attributed
to more than a decade and/or a cost of about USD 2.5 billion required to transform NPs
from hit compounds to drug candidates. These difficulties are connected to attempts to
balance efficacy and safety deficiencies and properties related to absorption, distribution,
metabolism, excretion, and toxicity (ADMET), which are crucial for the success of any drug
candidate [16–19]. Therefore, assessment of drug-likeness based on some key physicochem-
ical properties (PP) [19–22] is crucial at the early stage of drug discovery development (17).
A wide range of computational techniques can be used in modern drug discovery projects
to predict the drug-likeness of hit compounds [23]. Taking advantage of these tools, the
present study conducted cheminformatic analysis and data mining towards hit profiling,
hit prioritization, and hit optimization of AMNPs. The results revealed that most of the
AMNPs have the desired drug-like properties, and those with undesired properties may
be optimized to improve the desired properties. The process implemented in this study
could guide drug developers to realize the full prospects of available data on AMNPs in
the discovery of new antibiotics.
2. Results and Discussion
This study was set out to profile anti-MRSA NPs (AMNPs) for drug-likeness and to
identify their potential for “hit- to-“lead” optimization. The datasets (reportedly sourced
from plants, microbes, and marine organisms) consist of 111 AMNPs with their bioactivity
obtained from a recent literature search (Table S1, in the Supplementary Material). The
reported bioactivity of these compounds was normalized (Table S1) and grouped into three
classes: significantly active (SA), moderately active (MA), and negligibly active (NA). More
details of the procedures for data collection and preparation can be found in the method
section. Overall, the AMNPs were 45.9% SA, 40.5% MA, and 13.5% NA. The results and
implications of the findings from this study are provided below.
2.1. Molecular Descriptors and Physicochemical Properties of AMNPs and CDs
The key molecular descriptors and physicochemical properties of the overall AMNPs
and the different categories (SA, MA, and NA) were profiled for drug-likeness using
currently prescribed oral drugs for MRSA (CDs) (Figure S1, in the Supplementary Material)
as reference. Here we present the distribution of these properties and their implications.
2.1.1. Molecular Weight
Molecular weight (MW) is one of the key parameters required for oral bioavailabil-
ity [22]. Compounds with MW above 500 Dalton have been suggested to have a higher
tendency for absorption problems [20,21]. The results from this study depict that about
87% and 88% of the AMNPs and CDs have MW less than 500 Dalton (Figure 1a). The
mean of the AMNPs (389.3 Dalton) was not statistically different from that of the CDs
(427.2 Dalton), suggesting that most of the AMNPs will be bioavailable via the oral route.
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Figure 1. Distribution of the molecular weight of the datasets. (a) presents the distribution of AMNPs and CDs on a plot. 
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indicate the distribution of each of the datasets; the line that divides each of the boxes represents the median of the distri-
butions. The black bars in both figures indicate a 95% confidence interval. 
Additionally, most of the AMNPs could have “room” for the addition of required 
bioisosteres towards improving specific drug-like properties during the “hit”-to-“lead” 
optimization process. The few complex compounds in the CDs, mainly sourced from fun-
gus, may explain the higher MW observed in the CDs. The result for the distribution of 
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opti ization process. The few complex compounds in the CDs, mainly sourced from
f ngus, may explain t e higher MW observed in the CDs. The result for the istri ti f
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AMNPs were distributed below M of 500 Da, and their mean M , 366.47, 401.82, and
405.75 for MA, NA, and SA, respectively, were not significantly different (p > 0.05) from
that of the CDs (427.17) (Figure 1b). High MW has been associated with more significant
bioactivity because of the propensity/tendency of big compounds to encumber the binding
pockets of drug targets to bring about bioactivity [21,24]. This might explain why the
AMNPs with higher MW showed greater bioactivity.
2.1.2. Calculated Octanol/Water Partition Coefficient (cLogP)
The cLogP is used to estimate the hydrophilicity of a compound [25]. This descriptor
also contributes to drug-receptor interaction and the s lubility and absorption of bioactive
comp unds. Figure 2a illustrates the predicted distribution of cLogP for AMNPs compared
with the CDs.
Compounds with cLogP values above 5 are not likely to be well absorbed. This is
because high LogP tends to compromise the bioavailability of a bioactive molecule [26]. In
this study, the means of both AMNPS and CDs were lower than 5, and about 68% of the
AMNPs revealed cLogP values below 5 (Figure 2a). In addition, CDs had cLogP values
below 5, and about 60% of these compounds showed negative cLogP (Figure 2a). As shown
in Figure 2b, most of the compounds within each of the categories of AMNPs had cLogP
below 5, and the average mean values (NA = 2.45, MA = 4.1, SA = 3.27) were considerably
different (p < 0.05) from that of the reference compound (CDs = 0.12). This can be an
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Figure 2. Distribution of cLogP for the datasets. (a) is a swarm plot showing the cLogP of AMNPs and CDs. (b) shows a 
violin plot of the various categories of AMNPs and CDs where the boxes indicate the distribution of each of the datasets; 
the line that divides the boxes represents the median of the distributions. The average cLogP for all the categories of the 
AMNPs is significantly higher (p < 0.05) than that of the CDs. The black bars in both figures indicate a 95% confidence 
interval. 
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On the other hand, more positive cLogP values observed for AMNPs might indicate
that they are more hydrophobic than most CDs. The more hydrophobic a molecule is, the
more likely it is to bind to a target, resulting in greater bioactivity [26,27]. Therefore, the
correlation between the cLogP values of AMNPs and the reported bioactivity (particularly
those with MIC ≥ 1) was explored. Surprisingly, there was a weak negative correlation
(−0.074) between cLogP and the bioactivity of AMNPs (Figure S2, in the Supplementary
Material). This suggests that other molecular descriptors may have contributed to the
observed differences in the bioactivities of AM Ps.
2.1.3. Hydrogen Bond Acceptors and Donors
The hydrogen bond is a crucial property in drug–receptor interaction that may lead to
pharmacological action. It also plays a vital role in membrane transport and drug distribu-
tion in a biological system [28]. In this study, the most obvious observation r garding the
hydrog n bond was an accumulation of both CDs and AMNPs with few numbers: ≤10 for
hydroge ond acceptors (HBAs) and ≤5 for hydrog n bond on rs (HBDs). However,
the average hydrogen bonds for AMNPs (HBAs = 5.57 and HBDs = 3.14) were generally
lower (p < 0.05) than those for CDs (HBAs = 7.18 and HBDs = 3.65) (Figure 3a,b).
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2.1.4. Total Polar Surface Area (TPSA)
Studies have shown that molecules with TPSA above 140 Å2 are not likely to penetrate
through the intestinal membrane [29,30]. The results from this study depict that approxi-
mately 88% of AMNPs as against 53% of CDs had TPSA below 140 Å2. The mean of the
distribution also shows that both datasets were statistically different (p < 0.05) from each
other (Figure 5a).
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The TPSA was significantly higher (p < 0.05) in CDs than MA and SA categories.
Therefore, it can be inferred that most of the AMNPs (especially the MA and SA categories)
might have prospects for better intestinal epithelial permeability than the CDs, and that
they may be pursued in the development of anti-MRSA drug candidates. The higher
TPSA values observed for the CDs may relate to their large MW because there is a positive
correlation (r = 0.679) between these two parameters (MW and TPSA) (Figure S3, in the
Su plementary Material).
2.1.5. Rotatable Bond (RTB) Count
The number of RTBs has a direct e fect on the flexibility of a molecule. It is employed
to predict how compounds transverse the membrane. Therefore, it is used to determine
the bioavailability of compounds via the oral route and gastrointestinal absorption [31,32].
Previous studies have established an RTB value of not more than 10 as one of the selection
criteria for determining the oral bioavailability of drug candidates [22,32]. Our findings
reveal that all of the CDs and approximately 94% of the AMNPs had RTBs not more than
10, and the average value for both datasets (CDs = 4.82, AMNPs = 3.96) was not statistically
different (p > 0.05) from each other (Figure 6a).
As illustrated in Figure 6b, most of the compounds within each of the three categories
of AMNPs were distributed below RTBs of 10. However, the median RTBs for both MA
and SA [3] were the closest and most comparable to CDs [5]. The average distribution
of SA (4.59) also revealed the highest and most comparable AMNPs to the CDs, which
showed an average RTB of 4.82. Therefore, most of the AMNPs might have higher chances
of good oral absorption.
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2.2.1. Prediction of Absorption and Distribution
Some predictive rules have been developed to efficiently predict the oral absorption of
a molecule [33]. These rules provide guidelines for the early identification of compounds
with an increased chance of high oral absorption. In this study, the predictive rules of
Lipinski, Veber, and Egan were used to investigate the consistency of drug-likeness among
AMNPs with known anti-MRSA drugs (CDs).
Lipinski’s rule describes molecules with MW < 500, cLogP < 5, HBDs < 5, and
HBAs < 10 as more likely to have prospects for good oral absorption and permeation [21,32].
Figure 7 displays the results for compliance of the datasets with this rule. Overall, approxi-
mately 55% and 71% of AMNPs and CDs, respectively, passed Lipinski’s rule without any
violation (Figure 7a). Similarly, among the AMNP categories, 45%, 58%, and 80% of SA,
MA, and NA, respectively, obeyed the rule of five without any violation (Figure 7b).
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Figure 7. Histograms of the rule-of-five compliance based on the principle that drug-like compounds could break ≤ 1 of 
the rules. (a) shows that up to 71% and 55% of CDs and AMNPs, respectively, comply without any violation, while 85% 
of AMNPs violate not more than 1 of the rules. (b) shows that up to 88% of the CDs break not more than 1 of Lipinski’s 
rule, and among the AMNP categories, 45%, 58%, and 80% of SA, MA, and NA, respectively, obey the rule of five. 
Figure 7. Histograms of the rule-of-five compliance based on the principle that drug-like compounds could break ≤ 1 of the
rules. (a) shows that up to 71% and 55% of CDs and AMNPs, respectively, comply without any violation, whil 85% of
AMNPs violate not more than 1 of the rules. (b) shows that up to 88% of the CDs break not more than 1 of Lipinski’s rule,
and among the AMNP categories, 45%, 58%, and 80% of SA, MA, and NA, respectively, obey the rule of five.
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Lipinski mentioned that a compound that violates ≤ 1 of the rules can still be consid-
ered drug-like [32]. We set out to check the proportion of AMNPs that adhered to Lipinski’s
rule after violating not more than 1 of the parameters within the rule. Table 1 shows the
proportion of the compounds that would be left when MW was violated, and the rest of
the parameters were left alone, when cLogP was violated and the rest of the parameters
were within the rule, when HBAs were violated and the other properties obeyed the rule,
when HBDs were violated and the other three parameters complied with the rule. Overall,
up to 85% and 88% of AMNPs and CDs, respectively, obeyed Lipinski’s rule with not more
than one violation.
Table 1. The proportion of compounds that adhered to Lipinski’s rule when ≤ 1 of the parameters
was violated.







NA (n = 15) 12 13 12 12
MA (n = 45) 27 41 28 27
SA (n = 51) 25 41 26 25
AMNPs (n = 111) 64 95 66 64
CD (n = 17) 13 13 15 13
Among the categories of AMNPs, almost all (80% to 87%) of the NA molecules were
found within the space of this rule (Table 1). This might indicate that the less active
category of AMNPs (NA) has the potential to become orally active drugs. In another way,
this observation reinforces the idea that bioactivity does not guarantee that a compound
will be useful because drug-likeness is needed to determine the efficacy and selectivity of
such compound. Furthermore, the lower compliance observed among SA and MA might
suggest that there might be a need to optimize more for the physicochemical properties of
the active compounds (MA and SA categories) to balance their potency with efficiency. The
result obtained for oral absorption based on Veber’s rule (RTB ≤ 10 and TPSA ≤ 140 Å2) is
presented in Figure 8.
Overall, 86% of AMNPs and 53% of CDs were within the space of the rule. For the
AMNP categories, all compounds in NA, except tannic acid (TPSA = 777.98 and RTB = 31)
and punicalagin (TPSA = 518.76 and RTB = 0), were in compliance with Veber’s rule.
Additionally, more than 78% of both MA and SA categories obeyed the rule. Hence, there
are greater chances for most of the AMNPs to achieve permeability at Veber’s limits than
most of the currently prescribed anti-MRSA drugs.
Human intestinal absorption (HIA), permeation through the blood–brain barrier (BBB),
and drug assessment for substrates of p-glycoproteins (p-gp) are crucial pharmacokinetic
properties. They can be used in the early discovery process to determine the extent of
intestinal absorption of a bioactive compound in humans [33–36]. The result presented in
Figure 9 reveal that more than 77% of the AMNPs (compounds found within the white
and yellow regions) were likely to be passively absorbed.
The result also shows that 76% (red markers) of the AMNPs that showed the prospect
for HIA permeant might be non-p-gp substrates (i.e., not efflux from cells). Conversely,
for the reference data (CDs), about 41% were predicted to have high HIA; among these
compounds, 43% were non-p-gp substrates (Figure S4, in the Supplementary Material).
One of the crucial screenings during the early stage of the drug discovery process is to
check whether the biologically active molecules are substrates of p-gp. This is because p-gp
functions to decrease cellular uptake, absorption, oral bioavailability, distribution, and re-
tention time of drugs in the body through a unidirectional lipid flippase pathway [37]. The
p-gp can limit the effective concentration of bioactive molecules at the desired cellular sites,
leading to the rapid development of resistance, especially for anti-infective compounds.
Therefore, more than 76% AMNPs that were predicted as non-substrates of p-gp in this
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study could have prospects for good oral absorption and bioavailability. For the reference
compounds, sulfamethoxazole and chloramphenicol are a few examples of anti-MRSA
drugs that are known for their good absorption and bioavailability as contained in the
drug bank (www.drugbank.ca). On the other hand, omadacycline and doxycycline, among
others, are also known for their poor oral absorption (www.drugbank.ca). Therefore, the
present study is consistent with the established pharmacokinetic profile of CDs.
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Furthermore, it was observed that approximately 34% of the AMNPs (i.e., 38 out of the
total compounds) that showed a prospect for HIA (AMNPs found within the yellow region)
could permeate the BBB, while none of the CDs showed a propensity for permeation of
this barrier (Figure S4). The poor BBB permeability of the CDs could be because of their
negative average cLogP values. The BBB is a major hindrance in the development of drugs
for the central nervous system (CNS) [38]. This has made CNS infections that are caused
by multi-drug-resistant organisms, such as multi-drug-resistant Gram-negative aerobic
bacilli, MRSA, penicillin-resistant pneumococci, and other organisms, continually result
in serious health threats [37,38]. Therefore, the AMNPs with predicted BBB in this study
might be desirable for these CNS infections.
2.2.2. Predicted Metabolism of AMNPs and Identification of Their Metabolites
Orally administered drugs are prone to extensive biotransformation in the liver such
that their bioavailability and efficacy are extremely reduced [39]. Therefore, the propensity
for the metabolism of AMNPs by phase 1 and phase 2 enzymes was evaluated. The results
summarized in Table 2 reveal that 59% and 71% of AMNPs are likely to be metabolized by
phase 1 and 2 enzymes, respectively, while more than 50% of AMNPs may be metabolized
by both phase 1 and phase 2 enzymes.
Table 2. Prediction of phase 1 and 2 biotransformations of AMNPs.
1 No. of AMNPs that Formed Metabolites (n = 111)
Phase 1 66
Phase 2 79
Both phase 1 and 2 56
Without Metabolites 22
A total of 20% of the AMNPs are not likely to be transformed by phase 1 and phase
2 enzymes. The obtained result for phase 1 reveals that 60% of the AMNPs may suffer
the first-pass biotransformation while passing through the liver. This could consequently
reduce the bioavailability of these compounds before reaching their targets. In contrast, the
result for phase 2 shows that 71% of the AMNPs may produce metabolites at this stage,
implying that most of the AMNPs could be readily excreted out of the body. The structural
representation of the biotransformation result for one of the AMNPs (juncuenin D) is
presented in Figure 10 below.
Juncuenin D was metabolized to produce two and one metabolites in phase 1 and
phase 2, respectively. It has been reported that metabolites can cause adverse effects or
become active products in the pharmacology of the parent molecules [40]. Therefore,
biologically active categories of AMNPs (SA and MA) with pharmacologically active
metabolites might prospect for prolonged action of these compounds in the body. Similarly,
active metabolites formed by less active AMNPs (NA) may be considered further for
advancement rather than the parent compounds. Hence, recognizing the pharmacological
prospects of the AMNPs metabolite can be necessary to prevent their efficacy from being
compromised at a later stage of drug development [39,40].
2.2.3. Predicted CYP450 Inhibitory Potential of AMNPs
Potent inhibitors of CYP3A4 isozymes are not desirable in drug discovery as they
may result in drug–drug interactions [41]. The results from this study reveal that between
15% and 45% of the AMNPs returned “YES” for inhibition of one or more of the isozymes
(Figure 11a). A closer look at the AMNPs reveals that about 36 compounds (representing
41%, 27%, and 33% of NA, MA, and SA, respectively) might not inhibit any of the isoforms
(Figure 11b).
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tors of one or more CYP450 isozymes. (b) shows the percentage of the CD and AMNP categories that are non-inhibitors 
of CYP450 isozymes. 
Similarly, of all reference compounds (i.e., CDs) except DB225, cloxacillin was pre-
dicted as a non-inhibitor of CYP450 isoforms. Inhibition of CYP450 isoforms has led to the 
market withdrawal of many drugs, causing loss of valuable time and resources and drug 
lag [42]. Therefore, to avoid drug–drug interactions with current drugs and prevent the 
colossal waste that may come from the withdrawal of drug candidates at a later stage, in 
silico prediction of CYP enzyme inhibition for the AMNPs at the early stage of drug dis-
covery is desirable. The AMNPs predicted to inhibit CYP450 enzymes in this study should 
be given less consideration during hit selection irrespective of their bioactivity. This is 
because of their potential to interact with other drugs. 
2.2.4. Toxicity Profiling of AMNPs 
The prediction of the toxicity of drug candidates is one of the essential components 
of modern drug discovery. In this study, the toxicity of AMNPs was predicted by Osiris 
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Similarly, of all reference compounds (i.e., CDs) except DB225, cloxacillin was pre-
icted as a on-inhibitor of CYP450 isoforms. Inhibition of CYP450 isoforms has led to
the market withdrawal of many dru s, causing loss of valu ble time and resources and
drug lag [42]. Therefore, to avoid drug–drug interactions with c rrent rugs a d prevent
the colossal waste that may come from the ithdrawal of drug candidates at a later stage,
in silico prediction of CYP e zyme inhibition for the AMNPs at the early sta e of drug
discovery is desirable. The AMNPs predicted to inhibit CYP450 enzymes in this study
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should be given less consideration during hit selection irrespective of their bioactivity. This
is because of their potential to interact with other drugs.
2.2.4. Toxicity Profiling of AMNPs
The prediction of the toxicity of drug candidates is one of the essential components
of modern drug discovery. In this study, the toxicity of AMNPs was predicted by Osiris
DataWarrior software. The result reveals that about 58.6% and 53.9% of AMNPs and
CDs, respectively, may likely have negligible or no toxicity effects (Figure S5, in the
Supplementary Material). For the categories of AMNPs, at least 47%, 56%, and 59% of NA,
MA, and SA, respectively, returned “none” for all the toxicological parameters (data not
shown). Table 3 summarizes the compounds that show negligible or no undesired side
effects, such as mutagenicity, tumorigenicity, irritant, and reproductive effects.
Table 3. Summary of the estimated AMNPs and CDs with negligible or no undesired effects.
Class of Activity Mutagenicity Tumorigenicity Reproductive Effects Irritant Effects
CD (n = 17) 13 14 12 16
MA (n = 45) 40 41 36 38
NA (n = 15) 9 13 11 13
SA (n = 51) 44 49 37 46
Among the CDs, we observed that chloramphenicol (DB214) shows high toxicity
risk for all these toxicological properties. This observation builds on existing evidence
that chloramphenicol is likely to have mutagenic, tumorigenic, irritant, and reproductive
effects [43]. Toxicity has been estimated to be responsible for the attrition of approximately
33% of drug candidates, especially at the late stage of drug development. Therefore, early
identification of potentially toxic chemotypes can help to circumvent safety liabilities [44].
2.3. Synthetic Accessibility Score
It is assumed that molecular fragments that frequently occur among easily obtainable
compounds would be synthesized easily [45]. Hence, the synthetic accessibility score of
AMNPs was predicted to know their ease of being produced. The result with a value of 1
(easy to synthesize) to 10 (not easy to synthesize) is presented below (Figure 12).
Similarly, there was no difference (p > 0.05) between the average synthetic accessibility
score of the CDs and the AMNP categories (data not shown). However, most of the AMNPs
accumulate closer to a synthetic accessibility score of 1 rather than 10, suggesting that most
of the AMNPs could be synthesized with ease and that they are most unlikely to be rejected
due to synthesis-related problems.
2.4. Hit Prioritization of AMNPs
A balanced prioritization strategy that considers the physicochemistry and pharma-
cokinetics of bioactive compounds is vital for identifying molecules with the prospect to
become candidate drugs [19,44,46]. In this study, quantitative estimation of drug-likeness
(QED) described in Bickerton et al. [21] was used to prioritize the AMNPs. This was done
by combining the desirability of key molecular descriptors (MW, TPSA, HBA, HBD, logP,
RTBs, and aromatic rings, and ALERTs) into a single number that ranges between 0 and 1.
A score of 1 in this context describes any compound with all its physicochemical descriptors
within the space of an ideal drug-like profile. On the other hand, a score of 0 represents
a compound with undesired properties. The visualization of the AMNPs based on these
metrics is contained in Figure 13.
Molecules 2021, 26, 3674 13 of 22
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drug-likeness, which may aid their success in the discovery pipelines. Thus, there might
be a need to optimize more for potency among these compounds. A prioritized list of
the AMNPs is shown in Figure S6, in the Supplementary Material. Wunberg et al. [46]
conducted a data-driven screening of hits for drug-likeness and lead-likeness assessment.
They established that the most promising molecules have good potency and liabilities that
can easily be addressed. Therefore, some compounds with a poor balance of properties in
the active categories might be a good starting point for discovery and design since most
of them have room for optimization. Nevertheless, the identified liabilities of some of the
AMNPs might vary in severity, thus complicating the optimization process.
2.5. Desirability Scoring Function Allows In Silico Hit Optimization Strategies
The goal of preclinical drug discovery is to maintain desirable properties with suffi-
cient safety and improve on the identified liabilities in the lead compounds [47]. Therefore,
molecules with deficiencies in their physicochemical descriptors or toxicological properties
can be modified structurally for improvement [48]. In this study, two of the compounds
from the SA categories that were identified with liabilities were optimized for a good
balance of properties. The 2D structure of the compounds was drawn and modified using
ChemDraw software (version 12.0), and their molecular descriptors were estimated using
the MOE program (2019.01). The details of the selected compounds and processes are
described below.
α-Viniferin (DB169) is one of the AMNPs that had a good potency (6.2 µM) but
exhibited a low desirability score (0.143). Low absorption was one of the liabilities identified
with this compound. It was thus optimized by replacing each of its phenolic components
with a methyl (CH3) functional group (Figure 14a).
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Similarly, aminoethyl-chitosan (DB211) is another compound that showed a good
potency (0.147 µM) but a low desirability score (0.141). The poor pharmacokinetics and
drug-likeness properties of this molecule were improved by removing or replacing some
of its polar functional groups (OH and NH2). The details of this process are illustrated in
Figure 14b. The functional groups highlighted in the compound DB211 represent the group
of atoms that were strategically replaced (with a non-polar CH3 group) or removed during
the optimization process.
The compound ANA211 obtained in this process has a well-improved property and
better desirability score (0.808) (Figure S7, in the Supplementary Material). Interestingly,
both ANA169 and ANA211 also showed better synthetic accessibility scores than their
parent compounds (Figure S7). A search through the chemical database further revealed
no result for both analogues, implying that they might be representing novel chemotypes.
The quest for minimizing the high attrition rates at the latter stages of drug devel-
opment has necessitated the need to balance the efficacy of hit molecules with pharma-
cokinetic and toxicological properties through optimization [29,48,49]. In this study, the
characterization of the drug-likeness profile of AMNPs has allowed us to propose and
design multi-parameter hit optimization strategies for these compounds. This process is
essential for building up activity against undesired effects and, at the same time, keeping
the physicochemical properties in the drug-like range [50]. However, the bioactivity of the
novel compounds obtained in this study was not assessed. Structure–activity relationship
(SAR) or activity cliff will reveal which functional group is required for such bioactivity.
Therefore, optimization should be done with a knowledge of the SAR.
2.6. Exploration of the Molecular Similarity/Diversity within the AMNPs
To visualize the chemical space occupied by the AMNPs relative to the CDs, prin-
cipal component analysis (PCA) was conducted on the structural and physicochemical
properties of the datasets. PCA is a statistical approach used to visualize molecular similar-
ity/diversity within a molecule set [51]. It allows for the visualization of multidimensional
data on two- or three-dimensional plots with reduced loss of information [51,52]. The result
of the PCA for AMNPs relative to CDs is shown in Figure 15.
The first four components of the ChemGPS-NP Web map are interpreted as size,
aromaticity, lipophilicity, and flexibility for PS1, PS2, PS3, and PS4, respectively. The x-,
y-, and z-axes of the 3D plots are sPS2, PS3, and PS4, while PS1 represents the size of the
markers. Although CDs were distributed across the chemical space, AMNPs showed a
higher diversity (Figure 15). Furthermore, the plot showed that AMNPs were bigger than
CDs (PS1), and a closer look at PS2 showed that AMNPs were more aromatic than CDs.
Similarly, the plot on the y-axis reveals higher lipophilicity in favor of AMNPs, while the
diversity of AMNPs tends towards less flexibility (PS4) compared with CDs. Regarding
bioactivity, the significantly active (SA) category of the AMNPs was most diverse (data are
not shown).
Based on the principle of medicinal chemistry that similar compounds bind to similar
targets [52], few of the AMNPs that are highly far apart from the reference compounds
(CDs) may indicate their prospect for novel mechanisms of actions. In light of the fact
that most CDs are now known to be ineffective in treating MRSA infections, such active
compounds with potentials for novel biological targets are highly desirable for anti-MRSA
drug development.
Nevertheless, AMNPs situated closer to CDs in the chemical space may indicate
similar pharmacokinetics or drug-likeness prospects. This might suggest that few of the
AMNPs structurally related to CDs may have good pharmacokinetic properties and thus
pass through preclinical screening for anti-MRSA drug development. The concepts of
diversity and similarity of molecules are widely used in quantitative methods to design
(selecting) a representative set of molecules and analyze the relationship between chemical
structure and biological activity [16,51]. We further explored the relationship between the
chemical structure and biological activity of the AMNPs in this study.
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Figure 15. Distribution of AMNPs (blue markers) and CDs (red markers) in chemical space. The coor-
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2.7. Structure–Activity Relationship (SAR) Landscape
The analysis of structure–activity relationships (SAR) is one of the fundamental tasks
in medicinal chemistry. The underlying goal of exploring the SAR landscape is to identify
structural differences between molecules that lead to differences in their bioactivities [53,54].
Therefore, given a pair of structurally similar molecules that showed activity cliff, the
structure–activity landscape index (SALI) calculates how much potency is gained or lost,
while delta activity represents the difference in the activity of a pair of similar molecules [16].
The results of the exploration of SAR for the AMNPs are summarized in Figure 16.
Red-colored markers represent pairs of similar compounds with little or no difference
in bioactivity (see example in Figure 17). This is referred to as the smooth region (X) of the
SAR landscape.
Markers with pink, purple, and blue colors signify a pair of similar molecules with
widely different bioactivities. These regions (e.g., Y) are called activity cliffs of the SAR
landscape (Figure 18).
The concept of activity cliff is significant in identifying small structural modifications
associated with large changes in potency [54]. Therefore, those AMNPs (markers identified
with pink, purple, and blue colors, Figure 16) provide insight into potential functional
groups in the AMNPs that can modulate bioactivities. This concept can be used by medic-
inal chemists who are interested in lead optimization projects. Conversely, the smooth
region of the SAR landscape contains compounds that are good input data to build QSAR
models [55] The predicted SAR between the AMNPs is provided in Table S2.
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3. Materials and Methods
3.1. Data Collection and Preparation
An electronic search was conducted in May 2019 to identify relevant studies by
employing freely available public databases (Google Scholar, ScienceDirect, Scopus, and
PubMed). The keywords “marine OR natural products AND MRSA,” “phytochemicals
AND MRSA,” and “MIC of phytochemicals AND MRSA” were used. The last search date
was 20 May 2019. The reference lists of some of those eligible studies were also checked
for related studies. Studies that reported the susceptibility of clinical isolates of MRSA to
NPs, as determined by the reported minimum inhibitory concentration (MIC), were also
included in this study. The search was customized and limited to reported publications
from January 2009 to May 2019.
A total of 111 anti-MRSA natural products (AMNPs) with their in vitro bioactivity
(Table S1) were retrieved based on the search strategy described above. The “simplified
molecular input line entry system (SMILES)” structures of the AMNPs and their respective
bioactivity data were stored as a text file. The reported MIC value of the different AMNPs
(which ranged from 0.01 to 1600 µg/mL) was normalized. The datasets were divided into
three categories using a modification of the previously described methods [56–58]. The
normalized bioactivity categories include significantly active (SA) for MIC value below
2.5, moderately active (MA) for 2.5 < MIC ≤ 25, and negligibly active (NA) for MIC > 25.
The 111 AMNPs were made up of 51 (45.9%) SA, 45 (40.5%) MA, and 15 (13.5%) NA. In
addition, about 17 currently prescribed oral drugs for MRSA (CD) were also obtained
from drug bank (https://go.drugbank.com/drugs) and used as the reference compounds
(Figure S1).
3.2. Estimation of Molecular Descriptors and Physicochemical and Pharmacokinetic Properties of
the Datasets
The SMILES structures of the datasets, retrieved from PubChem (http://pubchem.
ncbi.nlm.nih.gov) [59], were uploaded onto the SwissADME [45] web server to estimate the
physicochemical properties of AMNPs. Molecular descriptors such as molecular weight,
hydrogen bonds, partition coefficient between n-octanol and water, rotatable bonds, and
polar surface area were also predicted with the MOE program (2019.01) [60]. The mean
values of these properties were calculated for the different bioactivity categories of AMNPs
and compared with those of the current drugs for MRSA (CDs). The SwissADME web tool
was used to predict the potential of each AMNP to inhibit the cytochrome P450 (CYP450)
enzymes. Biotransformation processes of the compounds were predicted by using a freely
available web service at www.biotransformer.ca (accessed on 22 November 2020) [61]. The
rules proposed by Lipinski, Veber, and Egan were used to evaluate the drug-likeness of the
AMNPs and CDs [45]. The absorption and bioavailability properties of AMNPs were also
estimated as described by Daina and Zoete [35]. Toxicity properties such as mutagenic,
tumorigenic, reproductive, and irritant effects were studied using Osiris DataWarrior
software [62].
3.3. Exploration of Chemical Space (Chemical Diversity)
ChemGPS-NP Web was used to explore the chemical space occupied by AMNPs
relative to CDs. The SMILES structure and identifier of the datasets were submitted in the
space provided on the ChemGPS-NP Web service (http://chemgps.bmc.uu.se) [52]. The
output with eight principal components added for each structure was retrieved as a text
file. The text file was visualized on a 3D scatter plot in Osiris DataWarrior software [62]
using the second (PS2), third (PS3), and fourth (PS4) principal components. Markers were
colored according to the categories of bioactivity, and the first principal component (PS1)
was used to size the markers.
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3.4. Data Analysis and Visualization
Scatter plots, violin plots, and bar charts of the molecular descriptors, physicochemical
properties, and other parameters estimated or predicted were plotted for AMNPs (and the
SA, MA, and NA categories) and CDs using DataWarrior [62], PlotsOfData web tool [63],
and Prism GraphPad 9.0 (GraphPad software). The mean of the molecular descriptors
and physicochemical properties for AMNPs (and the SA, MA, and NA categories) and
CDs were compared, and statistical differences were assessed with analysis of variance
(ANOVA), with significance set at p < 0.05. Furthermore, the association between the
in vitro activities (MIC) of AMNPs and the molecular descriptors or physicochemical
properties was assessed using the Bravais–Pearson correlation coefficient (r).
4. Conclusions
This study was aimed at profiling natural products with their known in vitro ac-
tivity against MRSA for drug-likeness and identifying their prospect for “hit”-to-“lead”
optimization. Profiling of molecular descriptors and physicochemical properties of the
datasets revealed that most of the AMNPs were not statistically different from the reference
compounds (CDs). In addition, among the AMNP categories, SA was the most comparable
to the reference compounds. Regarding drug-likeness, we observed that about 85% of
the AMNPs obeyed Lipinski and Veber’s rule. There are greater chances for most of the
AMNPs to achieve permeability at Veber’s limits than most of the currently prescribed
anti-MRSA drugs. Evaluation of their pharmacokinetic properties showed that more than
77% of the AMNPs might have the prospect for good oral absorption, and most of these
compounds are unlikely to be p-gp substrates.
Furthermore, about 34% of the AMNPs showed the prospect to become CNS drugs,
an added advantage over the known anti-MRSA drugs. The few AMNPs predicted as non-
inhibitors of CYP450 isoforms might be prioritized during hit selection. Toxicity profiling
also revealed that about 60% of these compounds have negligible or no adverse effect. In
addition, among the categories of AMNPs, NA exhibited the most promising prospect
for oral drugs, reinforcing the idea that bioactivity does not guarantee that a compound
will be useful. This result is relevant in drug discovery because poor physicochemical
properties, pharmacokinetics, and high toxicity effects have continued to account for the
most prominent cause of failure in drug discovery pipelines. Therefore, early information
on potential drug candidates is crucial for saving time and economic costs of development
[59,60]. This is because the process can potentially minimize the risk of future attrition.
However, the lower compliance observed among SA and MA might necessitate optimizing
more for their physicochemical properties towards balancing potency with efficacy.
The QED allows for the prioritization and identification of AMNPs with the desired
drug-likeness. Interestingly, two of the compounds with identified drug-likeness deficien-
cies were enhanced by random replacements of some parts of their functional groups to
evolve two promising and novel chemotypes with better synthetic accessibility scores.
Exploration of the structure–activity relationship also revealed activity cliffs (i.e., similar
compounds with significantly diverse activities), enabling the identification of chemical
groups responsible for enhanced anti-MRSA bioactivity. Overall, this study could be used
as a starting point in the pressing need for novel anti-MRSA therapies. Meanwhile, the
antimicrobial activity of the novel chemotypes identified in this study was not ascertained.
Furthermore, further in silico, in vitro, or in vivo studies are required to evaluate the
prospective drug activity and efficacy of the prioritized hits.
Supplementary Materials: The following are available online. Table S1: The selected AMNPs and
their reported anti-MRSA activity. Figure S1: The chemical structures of the antibiotics that were used
in the study. Figure S2: A scatter plot showing a weak negative correlation between cLogP and MIC
values for the AMNPs. Figure S3: A scatter plot showing a strong positive correlation between TPSA
and MW for the CDs. Figure S4: The BOILED-Egg predictive model for absorption and bioavailability
of CDs. Figure S5: Toxicity profiling of AMNPs and CDs. Figure S6: The prioritized list of the AMNPs.
Table S2: The estimated structure–activity relationship between the AMNP compounds.
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